Advertisement

The Social Imperative for Community Genetic Screening: An Australian Perspective

  • MaryAnne Aitken
  • Sylvia Metcalfe
Part of the International Library of Ethics, Law, and the New Medicine book series (LIME, volume 30)

In 10 years from now when we go for our driver’s licence, could we be asked to provide a quick cheek brush sample so that our DNA can be analysed to look for some important variations? For example, a variation in a gene that causes hypertrophic cardiomyopathy (HCM) that is associated with heart attack and sudden death.1,2 This has obvious and serious implications if a person is driving. If you do have this variation and are considered to be at high risk, it is possible to be fitted with a tiny monitor under your skin that can detect such an attack before it happens.3 Perhaps in future a person with the HCM gene variant who is considered to be at high risk will only be granted a driver’s licence on the condition that such a device is fitted.

Keywords

Cystic Fibrosis Alzheimer Disease Down Syndrome Newborn Screening Preimplantation Genetic Diagnosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

  1. 1.
    Marian, A. J. and Roberts, R. 1995. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 92: 1336–1347.PubMedGoogle Scholar
  2. 2.
    Ly, H. Q., Greiss, I., Talakic, M., Guerra, P. G., Macle, L., Thibault, B., Dubuc, M., and Roy, D. 2005. Sudden death and hypertrophic cardiomyopathy: a review. Canadian Journal of Cardiology 21: 441–448.PubMedGoogle Scholar
  3. 3.
    Crespo, E. M., Kim, J., and Selzman, K. A. 2005. The use of implantable cardioverter defibrillators for the prevention of sudden cardiac death: a review of the evidence and implications. American Journal of the Medical Sciences 329: 238–246.CrossRefPubMedGoogle Scholar
  4. 4.
    Nestler, E. J. 2001. Psychogenomics: opportunities for understanding addiction. The Journal of Neuroscience 21: 8324–8327.PubMedGoogle Scholar
  5. 5.
    Nestler, E. J. 2004. Molecular mechanisms of drug addiction. Neuropharmacology 47 (Suppl. 1): 24–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Morgan, T. H. 1910. Sex-linked inheritance in Drosophila. Science 32: 120–122.CrossRefPubMedGoogle Scholar
  7. 7.
    Morgan, T. H., Sturtevant, A. H., and Muller, H. J. 1915. The Mechanism of Mendelian Heredity. New York: Holt, Rhinehart & Winston.Google Scholar
  8. 8.
    Avery, O. T., MacLeod, C. M., and McCarty, M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumonococcus types. Journal of Experimental Medicine 79: 137–158.CrossRefPubMedGoogle Scholar
  9. 9.
    Bevis, D. C. 1952. The antenatal prediction of haemolytic disease of the newborn. The Lancet 1: 395–398.CrossRefGoogle Scholar
  10. 10.
    Watson, J. D. and Crick, F. H. C. 1953. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 171: 737–738.CrossRefPubMedGoogle Scholar
  11. 11.
    Tijo, H. J. and Levan, A. 1956. The chromosome numbers of man. Hereditas 42: 1–6.Google Scholar
  12. 12.
    Lejeune, J., Gautier, M., and Turpin, M. R. 1959. Etude des chromosomes somatiques de neuf enfants mongoliens. Comptes Rendus de l’Académie des Sciences (Paris) 248: 1721–1722.Google Scholar
  13. 13.
    McKusick, V. A. 1966. Mendelian Inheritance in Man; Catalogs of Autosomal Dominant, Autosomal Recessive, and X-Linked Phenotypes. Baltimore, MD: Johns Hopkins Press.Google Scholar
  14. 14.
    Bell, G. I., Pictet, R. L., Rutter, W. J., Cordell, B., Tischer, E., and Goodman, H. M. 1980. Sequence of the human insulin gene. Nature 284: 26–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L. et al., 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073.CrossRefPubMedGoogle Scholar
  16. 16.
    Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., and King, M. C. 1994. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genetics 8: 399–404.CrossRefPubMedGoogle Scholar
  17. 17.
    Wooster, R. and Weber, B. L. 2003. Breast and ovarian cancer. New England Journal of Medicine 348: 2339–2347.CrossRefPubMedGoogle Scholar
  18. 18.
    Price, D. T. and Ridker, P. M. 1997. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Annals of Internal Medicine 127: 895–903.PubMedGoogle Scholar
  19. 19.
    De Stefano, V., Martinelli, I., Mannucci, P. M., Paciaroni, K., Chiusolo, P., Casorelli, I., Rossi, E., and Leone, G. 1999. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. New England Journal of Medicine 341: 801–806.CrossRefPubMedGoogle Scholar
  20. 20.
    Primhak, R. A. and Tanner, M. S. 2001. Alpha-1 antitrypsin deficiency. Archives of Diseases in Childhood 85: 2–5.CrossRefGoogle Scholar
  21. 21.
    Sveger, T. and Thelin, T. 2000. A future for neonatal alpha1-antitrypsin screening. Acta Paediatrica 89: 259–261.CrossRefPubMedGoogle Scholar
  22. 22.
    Ferrandi, M. and Bianchi, G. 2000. Genetic mechanisms underlying the regulation of urinary sodium excretion and arterial blood pressure: the role of adducin. Acta Physiologica Scandinavia 168: 187–193.CrossRefGoogle Scholar
  23. 23.
    Li, Y., Thijs, L., Kuznetsova, T., Zagato, L., Struijker-Boudier, H., Bianchi, G., and Staessen, J. A. 2005. Cardiovascular risk in relation to alpha-adducin Gly460Trp polymorphism and systolic pressure: a prospective population study. Hypertension 46: 527–532.CrossRefPubMedGoogle Scholar
  24. 24.
    Goldstein, J. L. and Brown, M. S. 2001. Molecular medicine: the cholesterol quartet. Science 292: 1310–1312.CrossRefPubMedGoogle Scholar
  25. 25.
    Ralston, S. H. 2002. Genetic control of susceptibility to osteoporosis. Journal of Clinical Endocrinology and Metabolism 87: 2460–2466.CrossRefPubMedGoogle Scholar
  26. 26.
    van Tilburg, J., van Haeften, T. W., Pearson, P., and Wijmenga, C. 2001. Defining the genetic contribution of type 2 diabetes mellitus. Journal of Medical Genetics 38: 569–578.CrossRefPubMedGoogle Scholar
  27. 27.
    Barroso, I. 2005. Genetics of type 2 diabetes. Diabetic Medicine 22: 517–535.CrossRefPubMedGoogle Scholar
  28. 28.
    Humphries, S. E., Talmud, P. J., Hawe, E., Bolla, M., Day, I. N., and Miller, G. J. 2001. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358: 115–119.CrossRefPubMedGoogle Scholar
  29. 29.
    Humphries, S. E., Hawe, E., Dhamrait, S., Miller, G. J., and Talmud, P. J. 2003. In search of genetic precision. Lancet 361: 1908–1909.CrossRefPubMedGoogle Scholar
  30. 30.
    Hirschhorn, J. N. 2005. Genetic approaches to studying common diseases and complex traits. Pediatric Research 57: 74R–77R.CrossRefPubMedGoogle Scholar
  31. 31.
    Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., Meldrim, J., Mesirov, J. P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange-Thomann, N., Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J. C., Mungall, A., Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston, R. H., Wilson, R. K., Hillier, L. W., McPherson, J. D., Marra, M. A., Mardis, E. R., Fulton, L. A., Chinwalla, A. T., Pepin, K. H., Gish, W. R., Chissoe, S. L., Wendl, M. C., Delehaunty, K. D., Miner, T. L., Delehaunty, A., Kramer, J. B., Cook, L. L., Fulton, R. S., Johnson, D. L., Minx, P. J., Clifton, S. W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T., Doggett, N., Cheng, J. F., Olsen, A., Lucas, S., Elkin, C., Uberbacher, E., Frazier, M., Gibbs, R. A., Muzny, D. M., Scherer, S. E., Bouck, J. B., Sodergren, E. J., Worley, K. C., Rives, C. M., Gorrell, J. H., Metzker, M. L., Naylor, S. L., Kucherlapati, R. S., Nelson, D. L., Weinstock, G. M., Sakaki, Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T., Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier, E., Robert, C., Wincker, P., Smith, D. R., Doucette- Stamm, L., Rubenfield, M., Weinstock, K., Lee, H. M., Dubois, J., Rosenthal, A., Platzer, M., Nyakatura, G., Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, L., Rowen, L., Madan, A., Qin, S., Davis, R. W., Federspiel, N. A., Abola, A. P., Proctor, M. J., Myers, R. M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D. R., Olson, M. V., Kaul, R., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G. A., Athanasiou, M., Schultz, R., Roe, B. A., Chen, F., Pan, H., Ramser, J., Lehrach, H., Reinhardt, R., McCombie, W. R., de la Bastide, M., Dedhia, N., Blocker, H., Hornischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey, J. A., Bateman, A., Batzoglou, S., Birney, E., Bork, P., Brown, D. G., Burge, C. B., Cerutti, L., Chen, H. C., Church, D., Clamp, M., Copley, R. R., Doerks, T., Eddy, S. R., Eichler, E. E., Furey, T. S., Galagan, J., Gilbert, J. G., Harmon, C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., Johnson, L. S., Jones, T. A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W. J., Kitts, P., Koonin, E. V., Korf, I., Kulp, D., Lancet, D., Lowe, T. M., McLysaght, A., Mikkelsen, T., Moran, J. V., Mulder, N., Pollara, V. J., Ponting, C. P., Schuler, G., Schultz, J., Slater, G., Smit, A. F., Stupka, E., Szustakowski, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., Wallis, J., Wheeler, R., Williams, A., Wolf, Y. I., Wolfe, K. H., Yang, S. P., Yeh, R. F., Collins, F., Guyer, M. S., Peterson, J., Felsenfeld, A., Wetterstrand, K. A., Patrinos, A., Morgan, M. J., Szustakowki, J., de Jong, P., Catanese, J. J., Osoegawa, K., Shizuya, H., Choi, S., and Chen, Y. J. 2001. Initial sequencing and analysis of the human genome. Nature 409: 860–921.CrossRefPubMedGoogle Scholar
  32. 32.
    OMIM Online Mendelian Inheritance in Man 2004, available at <www.ncbi.nlm.nih.gov/ entrez/query.fcgi?db¼OMIM>.
  33. 33.
    Barratt, A. L., Cockburn, J., Redman, S., Paul, C., and Perkins, J. 1997. Mammographic screening: results from the 1996 National Breast Health Survey. Medical Journal of Australia 167: 521–524.PubMedGoogle Scholar
  34. 34.
    Australian Institute of Health and Welfare 2000. Cervical screening in Australia 1997–1998. AIHW Catalogue No. 9. Canberra: AIHW, 2000: 36, available at <http://www.aihw.gov.au/ publications/can/csa97-8/csa97–8.pdf>.
  35. 35.
    HGSA Policy 2004. Antenatal screening for Down’s syndrome and other fetal aneuploidy, available at <http://www.hgsa.com.au/>.
  36. 36.
    Wilcken, B. M. 2003. Does every baby get a newborn screening test? Medical Journal of Australia 179: 400–401.PubMedGoogle Scholar
  37. 37.
    Wilcken, B., Wiley, V., Hammond, J., and Carpenter, K. 2003. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England Journal of Medicine 348: 2304–2312.CrossRefPubMedGoogle Scholar
  38. 38.
    HGSA Guidelines 2003. Guidelines for testing for fragile X syndrome, available at <http://www.hgsa.com.au/>.
  39. 39.
    Turner, G., Robinson, H., Wake, S., Laing, S., and Partington, M. 1997. Case finding for the fragile X syndrome and its consequences. British Medical Journal 315: 1223–1226.PubMedGoogle Scholar
  40. 40.
    Gason, A. A., Sheffield, E., Bankier, A., Aitken, M. A., Metcalfe, S., Barlow-Stewart, K., and Delatycki, M. B. 2003. Evaluation of a Tay-Sachs disease screening program. Clinical Genetics 63: 386–392.CrossRefPubMedGoogle Scholar
  41. 41.
    Barlow-Stewart, K., Burnett, L., Proos, A., Howell, V., Huq, F., Lazarus, R., and Aizenberg, H. 2003. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. Journal of Medical Genetics 40: 45.CrossRefGoogle Scholar
  42. 42.
  43. 43.
    Sydney Ultrasound for Women 2002, available at <http://sufw.com.au/>.
  44. 44.
    Wilson, J. M. and Jungner, G. 1968. Principles and Practice of Screening for Disease. Geneva: World Health Organization.Google Scholar
  45. 45.
    National Research Council (U.S.). Committee for the Study of Inborn Errors of Metabolism. 1975. Genetic Screening: Programs, Principles, and Research. Washington, DC: National Academy of Sciences.Google Scholar
  46. 46.
    Collins, V. and Williamson, R. 2003. Providing services for families with a genetic condition: a contrast between cystic fibrosis and Down’s syndrome. Pediatrics 112: 1177–1180.CrossRefPubMedGoogle Scholar
  47. 47.
    Beutler, E., Boggs, D. R., Heller, P., Maurer, A., Motulsky, A. G., and Sheehy, T. W. 1971. Hazards of indiscriminate screening for sickly. New England Journal Medicine 285: 1485–1486.CrossRefGoogle Scholar
  48. 48.
    Hampton, M. L., Anderson, J., Lavizzo, B. S., and Bergmen, A. B. 1974. Sickle cell ‘‘nondisease.’’ A potentially serious public health problem. American Journal of Diseases of Children 128: 58–61.Google Scholar
  49. 49.
    Rotter, J. I. and Diamond, J. M. 1987. What maintains the frequencies of human genetic diseases? Nature 329: 289–290.CrossRefPubMedGoogle Scholar
  50. 50.
    Modell, B. and Modell, M. 1992. Towards a Healthy Baby: Congenital Disorders and the New Genetics in Primary Care. Oxford: Oxford University Press, 358–359.Google Scholar
  51. 51.
    Mueller, R. F. and Young, I. D. 2001. Emery’s Elements of Medical Genetics, 11th edn. Edinburgh: Churchill Livingstone, 372.Google Scholar
  52. 52.
    Modell and Modell, ibid., 359–361.Google Scholar
  53. 53.
    Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M. X., and Phelps, C. H. 1998. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centres Consortium on Apolipoprotein E and Alzheimer’s Disease. New England Journal of Medicine 338: 506–511.CrossRefPubMedGoogle Scholar
  54. 54.
    Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., Myers, R. H., Pericak-Vance, M. A., Risch, N., and van Duijn, C. M. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Journal of the American Medical Association 278: 1349–1356.CrossRefPubMedGoogle Scholar
  55. 55.
    Yip, A. G., Brayne, C., Easton, D., Rubinsztein, D. C., and Medical Research Council Cognitive Function Ageing Study. 2002. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. Journal of Medical Genetics 39: 639–643.Google Scholar
  56. 56.
    Panegyres, P. K., Goldblatt, J., Walpole, I., Connor, C., Liebeck, T., and Harrop, K. 2000. Genetic testing for Alzheimer’s disease. Medical Journal of Australia 172: 339–343.PubMedGoogle Scholar
  57. 57.
    Post, S. G., Whitehouse, P. J., Binstock, R. H., Bird, T. D., Eckert, S. K., Farrer, L. A., Fleck, L. M., Gaines, A. D., Juengst, E. T., Karlinsky, H., Miles, S., Murray, T. H., Quaid, K. A., Relkin, N. R., Roses, A. D., St George-Hyslop, P. H., Sachs, G. A., Steinbock, B., Truschke, E. F., and Zinn, A. B. 1997. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. Journal of the American Medical Association 277: 832–836.CrossRefPubMedGoogle Scholar
  58. 58.
    Bird, T. D. 2005. Genetic factors in Alzheimer’s disease. New England Journal of Medicine 352: 862–864.CrossRefPubMedGoogle Scholar
  59. 59.
    Jonsen, A. R., Durfy, S. J., Burke, W., and Motulsky, A. G. 1996. The advent of the ‘‘unpatients’’. Nature Medicine 2: 622–624.CrossRefPubMedGoogle Scholar
  60. 60.
    Broadstock, M., Michie, S., and Marteau, T. 2000. Psychological consequences of predictive genetic testing: a systematic review. European Journal of Human Genetics 8: 731–738.CrossRefPubMedGoogle Scholar
  61. 61.
    Davison, C., 1996 in The troubled helix. Social and psychological implications of the new human genetics, edited by T. Marteau and M. P. M. Richards, Cambridge University Press, Cambridge, pp. 317–330.Google Scholar
  62. 62.
    Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., and Sadee, W. 2001. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Journal of the American Medical Association 286: 2270–2279.CrossRefPubMedGoogle Scholar
  63. 63.
    Mueller, R. and Young, I. 2001. op.cit. pp. 169–170.Google Scholar
  64. 64.
    Collins, F. S. 1999. Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics 54: 41–47.PubMedGoogle Scholar
  65. 65.
    Roses, A. D. 2000a. Pharmacogenetics and the practice of medicine. Nature 405: 857–865.CrossRefPubMedGoogle Scholar
  66. 66.
    Evans, W. E. and Relling, M. V. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487–491.CrossRefPubMedGoogle Scholar
  67. 67.
    Roses, A. D. 2000a. op.cit.Google Scholar
  68. 68.
    Roses, A. D. 2000b. Pharmacogenetics and future drug development and delivery. Lancet 355: 1358–1361.CrossRefPubMedGoogle Scholar
  69. 69.
  70. 70.
    Glasziou, P. P. and Irwig, L. M. 1997. Mammographic screening in Australia. Medical Journal of Australia 167: 516–517.PubMedGoogle Scholar
  71. 71.
    Barratt, A. L. et al. 1997. op.cit.Google Scholar
  72. 72.
    Australian Institute of Health and Welfare 2000. op. cit.Google Scholar
  73. 73.
    Walpole, I. R., Watson, C., Moore, D., Goldblatt, J., and Bower, C. 1997. Evaluation of a project to enhance knowledge of hereditary diseases and management. Journal of Medical Genetics 34: 831–837.CrossRefPubMedGoogle Scholar
  74. 74.
    Dietrich, H. and Schibeci, R. 2003. Beyond public perceptions of gene technology: community participation in public policy in Australia. Public Understanding of Science 12: 381–401.CrossRefPubMedGoogle Scholar
  75. 75.
    Australian Law Reform Commission Report 96. 2003. Essentially Yours: The Protection of Human Genetic Information in Australia <http://www.austlii.edu.au/au/other/alrc/ publications/reports/96/ALRC96.rtf/>. Australian Government Printers.
  76. 76.
    Wilcken, B. M. 2003. op.cit.Google Scholar
  77. 77.
    Metz, M. P., Ranieri, E., Gerace, R. L., Priest, K. R., Luke, C. G., and Chan, A. 2003. Newborn screening in South Australia: is it universal? Medical Journal of Australia 179: 412–415.PubMedGoogle Scholar
  78. 78.
    Suriadi, C., Jovanovska, M., and Quinlivan, J. A. 2004. Factors affecting mothers’ knowledge of genetic screening. Australian and New Zealand Journal of Obstetrics and Gynaecology 44: 30–34.CrossRefPubMedGoogle Scholar
  79. 79.
    Mulvey, S. and Wallace, E. M. 2001. Levels of knowledge of Down’s syndrome and Down’s syndrome testing in Australian women. Australian and New Zealand Journal of Obstetrics and Gynaecology 41: 167–169.CrossRefPubMedGoogle Scholar
  80. 80.
    Mulvey, S. and Wallace, E. M. 2000. Women’s knowledge of and attitudes to first and second trimester screening for Down’s syndrome. British Journal of Obstetrics and Gynaecology 107: 1302–1305.PubMedGoogle Scholar
  81. 81.
    Rostant, K., Steed, L., and O’Leary, P. 2003. Survey of the knowledge, attitudes and experiences of Western Australian women in relation to prenatal screening and diagnostic procedures. Australian and New Zealand Journal of Obstetrics and Gynaecology 43: 134–138.CrossRefPubMedGoogle Scholar
  82. 82.
    Halliday, J. L., Warren, R., McDonald, G., Rice, P. L., Bell, R. J., and Watson, L. F. 2001. Prenatal diagnosis for women aged 37 years and over: to have or not to have. Prenatal Diagnosis 21: 842–847.CrossRefPubMedGoogle Scholar
  83. 83.
    Suriadi, C. et al. 2003. op.cit.Google Scholar
  84. 84.
    Gason, A. et al. 2003. op.cit.Google Scholar
  85. 85.
    Gordon, C., Walpole, I., Zubrick, S. R., and Bower, C. 2003. Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later. American Journal of Medical Genetics 120A: 199–208.CrossRefPubMedGoogle Scholar
  86. 86.
    Barlow Stewart, K. et al. 2003. op.cit.Google Scholar
  87. 87.
    Wake, S. A., Rogers, C. J., Colley, P. W., Hieatt, E. A., Jenner, C. F., and Turner, G. M. 1996. Cystic fibrosis carrier screening in two New South Wales country towns. Medical Journal of Australia 164: 471–474.PubMedGoogle Scholar
  88. 88.
    Collins, V., Halliday, J., Kahler, S., and Williamson, R. 2001. Parents’ experiences with genetic counseling after the birth of a baby with a genetic disorder: an exploratory study. Journal of Genetic Counseling 10: 53–72.CrossRefGoogle Scholar
  89. 89.
    Nisselle, A. E., Delatycki, M. B., Collins, V., Metcalfe, S. Aitken, M. A. du Sart, D., Halliday, J., Macciocca, I., Wakefield, A., Hill, V., Gason, A., Warner, B., Calabro, V., Williamson, R., and Allen, K. J. 2004. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis. Clinical Genetics 65: 358–367.CrossRefPubMedGoogle Scholar
  90. 90.
    Delatycki, M. B., Allen, K. J., Nisselle, A. E., Collins, V., Metcalfe, S., du Sart, D., Halliday, J., Aitken, M. A., Macciocca, I., Hill, V., et al. 2005. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 366: 314–316.CrossRefPubMedGoogle Scholar
  91. 91.
    Olynyk, J. K., Cullen, D. J., Aquilia, S., Rossi, E., Summerville, L., and Powell, L. W. 1999. A population-based study of the clinical expression of the hemochromatosis gene. New England Journal of Medicine 341: 718–724.CrossRefPubMedGoogle Scholar
  92. 92.
    Beutler, E., Felitti, V. J., Koziol, J. A., Ho, N. J., and Gelbart, T. 2002. Penetrance of 845G!A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359: 211–218.CrossRefPubMedGoogle Scholar
  93. 93.
    Gertig, D. M., Hopper, J. L., and Allen, K. J. 2003. Population genetic screening for hereditary haemochromatosis. Medical Journal of Australia 179: 517–518.PubMedGoogle Scholar
  94. 94.
    Imperatore, G., Pinsky, L. E., Motulsky, A., Reyes, M., Bradley, L. A., and Burke, W. 2003. Hereditary hemochromatosis: Perspectives of public health, medical genetics, and primary care. Genetics in Medicine 5: 1–8.CrossRefPubMedGoogle Scholar
  95. 95.
    Gason, A. A., Aitken, M. A., Metcalfe, S. A., Allen, K., and Delatycki, M. B. 2004. Genetic susceptibility screening in schools: attitudes of the school community towards hereditary haemochromatosis. Clinical Genetics 67: 166–174.CrossRefGoogle Scholar
  96. 96.
    Jackson, L. 2003. Fetal cells and DNA in maternal blood. Prenatal Diagnosis 23: 837–846.CrossRefPubMedGoogle Scholar
  97. 97.
    Ng, E. K., Tsui, N. B., Lau, T. K., Leung, T. N., Chiu, R. W., Panesar, N. S., Lit, L. C., Chan, K. W., and Lo, Y. M. 2003. mRNA of placental origin is readily detectable in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America 100: 4748–4753.CrossRefPubMedGoogle Scholar
  98. 98.
    Beskow, L. M., Khoury, M. J., Baker, T. G., and Thrasher, J. F. 2001. The integration of genomics into public health research, policy and practice in the United States. Community Genetics 4: 2–11.CrossRefPubMedGoogle Scholar
  99. 99.
    Halliday, J. L., Collins, V. R., Aitken, M. A., Richards, M. P. M., and Olsson, C. A. 2004. Genetics and public health - evolution, or revolution? Journal of Epidemiology and Community Health 58(11):894–9.CrossRefPubMedGoogle Scholar
  100. 100.
    Ouhibi, N., Olson, S., Patton, P., and Wolf, D. 2001. Preimplantation genetic diagnosis. Current Women’s Health Reports 1: 138–142.PubMedGoogle Scholar
  101. 101.
    Lockhart, D. J. and Winzeler, E. A. 2000. Genomics, gene expression and DNA arrays. Nature 405: 827–836.CrossRefPubMedGoogle Scholar
  102. 102.
    Kerr, A. and Shakespeare, T. 2002. Gene politics : from eugenics to genome. New Clarion press, Cheltenham.Google Scholar
  103. 103.
    Dietrich, H. and Schibeci, R. 2003. op.cit.Google Scholar
  104. 104.
    Bubela, T. M. and Caulfield, T. A. 2004. Do the print media ‘‘hype’’ genetic research? A comparison of newspaper stories and peer-reviewed research papers. Canadian Medical Association Journal 170: 1399–1407.CrossRefPubMedGoogle Scholar
  105. 105.
    Metcalfe, S., Hurworth, R., Newstead, J., and Robins, R. 2002. Needs assessment study of genetics education for general practitioners in Australia. Genetics in Medicine 4: 71–77.CrossRefPubMedGoogle Scholar
  106. 106.
    Newstead, J., Delatycki, M. B., and Aitken, M. A. 2002. Haemochromatosis and family testing, what should a GP do? Australian Family Physician 31: 533–537.PubMedGoogle Scholar
  107. 107.
    Crawford, M. J., Rutter, D., Manley, C., Weaver, T., Bhui, K., Fulop, N., and Tyrer, P. 2002. Systematic review of involving patients in the planning and development of health care. British Medical Journal 325: 1263.CrossRefPubMedGoogle Scholar
  108. 108.
    Halliday, J. et al. 2004. op.cit.Google Scholar
  109. 109.
    Beskow, L. M. et al. 2001. op.cit.Google Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  • MaryAnne Aitken
    • 1
  • Sylvia Metcalfe
  1. 1.Department of PaediatricsUniversity of MelbourneAustralia

Personalised recommendations